Literature DB >> 29446123

Associations between CSF cortisol and CSF norepinephrine in cognitively normal controls and patients with amnestic MCI and AD dementia.

Lucy Y Wang1,2, Murray A Raskind1,2, Charles W Wilkinson3,2, Jane B Shofer2, Carl Sikkema3, Patricia Szot1, Joseph F Quinn4, Douglas R Galasko5, Elaine R Peskind1,2.   

Abstract

OBJECTIVE: This study evaluated the effects of Alzheimer disease (AD) on the relationship between the brain noradrenergic system and hypothalamic pituitary adrenocortical axis (HPA). Specifically, relationships between cerebrospinal fluid (CSF) norepinephrine (NE) and CSF cortisol were examined in cognitively normal participants and participants with AD dementia and amnestic mild cognitive impairment (aMCI). We hypothesized that there would a positive association between these 2 measures in cognitively normal controls and that this association would be altered in AD.
METHODS: Four hundred twenty-one CSF samples were assayed for NE and cortisol in controls (n = 305), participants with aMCI (n = 22), and AD dementia (n = 94). Linear regression was used to examine the association between CSF cortisol and NE, adjusting for age, sex, education, and body mass index.
RESULTS: Contrary to our hypothesis, CSF cortisol and NE levels were not significantly associated in controls. However, higher cortisol levels were associated with higher NE levels in AD and aMCI participants. Regression coefficients ± standard errors for the change in cortisol per 100-pg/mL increase in NE are as follows: controls 0.0 ± 0.2, P = 1.0; MCI, 1.4 ± 0.7, P = .14; and AD 1.1 ± 0.4, P = .032. Analysis with MCI and AD participants combined strengthened statistical significance (1.2 ± 0.3, P = .007).
CONCLUSIONS: Enhanced responsiveness of the HPA axis to noradrenergic stimulatory regulation in AD and disruption of the blood brain barrier may contribute to these findings. Because brainstem noradrenergic stimulatory regulation of the HPA axis is substantially increased by both acute and chronic stress, these findings are also consistent with AD participants experiencing higher levels of acute and chronic stress.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Alzheimer disease; cerebrospinal fluid; cortisol; mild cognitive impairment; norepinephrine; stress

Mesh:

Substances:

Year:  2018        PMID: 29446123      PMCID: PMC5882504          DOI: 10.1002/gps.4856

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  32 in total

1.  Disease-specific patterns of locus coeruleus cell loss.

Authors:  D C German; K F Manaye; C L White; D J Woodward; D D McIntire; W K Smith; R N Kalaria; D M Mann
Journal:  Ann Neurol       Date:  1992-11       Impact factor: 10.422

2.  Increased CSF cortisol in AD is a function of APOE genotype.

Authors:  E R Peskind; C W Wilkinson; E C Petrie; G D Schellenberg; M A Raskind
Journal:  Neurology       Date:  2001-04-24       Impact factor: 9.910

3.  Changes with aging of steroidal levels in the cerebrospinal fluid of women.

Authors:  K Murakami; T Nakagawa; M Shozu; K Uchide; K Koike; M Inoue
Journal:  Maturitas       Date:  1999-09-24       Impact factor: 4.342

4.  Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type.

Authors:  J C Morris
Journal:  Int Psychogeriatr       Date:  1997       Impact factor: 3.878

5.  Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies.

Authors:  Patricia Szot; Sylvia S White; J Lynne Greenup; James B Leverenz; Elaine R Peskind; Murray A Raskind
Journal:  J Neurosci       Date:  2006-01-11       Impact factor: 6.167

6.  Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes.

Authors:  P Szot; S S White; J L Greenup; J B Leverenz; E R Peskind; M A Raskind
Journal:  Neuroscience       Date:  2007-02-26       Impact factor: 3.590

7.  Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection.

Authors:  C Holmes; G Eisenhofer; D S Goldstein
Journal:  J Chromatogr B Biomed Appl       Date:  1994-03-04

8.  Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression.

Authors:  Lucy Y Wang; Jane B Shofer; Kirsten Rohde; Kim L Hart; David J Hoff; Yun H McFall; Murray A Raskind; Elaine R Peskind
Journal:  Am J Geriatr Psychiatry       Date:  2009-09       Impact factor: 4.105

9.  Cerebrospinal fluid norepinephrine and cognition in subjects across the adult age span.

Authors:  Lucy Y Wang; Richard R Murphy; Brett Hanscom; Ge Li; Steven P Millard; Eric C Petrie; Douglas R Galasko; Carl Sikkema; Murray A Raskind; Charles W Wilkinson; Elaine R Peskind
Journal:  Neurobiol Aging       Date:  2013-04-30       Impact factor: 4.673

10.  Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins.

Authors:  M Uhr; F Holsboer; M B Müller
Journal:  J Neuroendocrinol       Date:  2002-09       Impact factor: 3.627

View more
  4 in total

Review 1.  Alzheimer's disease: risk factors and potentially protective measures.

Authors:  Marcos Vinícius Ferreira Silva; Cristina de Mello Gomide Loures; Luan Carlos Vieira Alves; Leonardo Cruz de Souza; Karina Braga Gomes Borges; Maria das Graças Carvalho
Journal:  J Biomed Sci       Date:  2019-05-09       Impact factor: 8.410

Review 2.  Sleep, Cognition and Cortisol in Addison's Disease: A Mechanistic Relationship.

Authors:  Michelle Henry; Kevin Garth Flusk Thomas; Ian Louis Ross
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-27       Impact factor: 5.555

3.  Anterior Pituitary Hormones in Blood and Cerebrospinal Fluid of Patients in Neurocritical Care.

Authors:  Henriette Beyer; Nicole Lange; Armin H Podtschaske; Jan Martin; Lucia Albers; Alexander von Werder; Jürgen Ruland; Gerhard Schneider; Bernhard Meyer; Simone M Kagerbauer; Jens Gempt
Journal:  touchREV Endocrinol       Date:  2022-06-13

4.  Cerebrospinal Fluid Cortisol and Dehydroepiandrosterone Sulfate, Alzheimer's Disease Pathology, and Cognitive Decline.

Authors:  Sami Ouanes; Christopher Clark; Jonas Richiardi; Bénédicte Maréchal; Piotr Lewczuk; Johannes Kornhuber; Clemens Kirschbaum; Julius Popp
Journal:  Front Aging Neurosci       Date:  2022-07-07       Impact factor: 5.702

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.